Patents by Inventor Nathalie Mielcarek
Nathalie Mielcarek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220378898Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.Type: ApplicationFiled: February 9, 2022Publication date: December 1, 2022Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
-
Patent number: 11285201Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.Type: GrantFiled: February 11, 2020Date of Patent: March 29, 2022Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
-
Publication number: 20200171139Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.Type: ApplicationFiled: February 11, 2020Publication date: June 4, 2020Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
-
Patent number: 10610580Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.Type: GrantFiled: February 18, 2019Date of Patent: April 7, 2020Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
-
Publication number: 20190175719Abstract: A mutated Bordetella strain comprising at least a mutated ptr gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.Type: ApplicationFiled: February 18, 2019Publication date: June 13, 2019Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
-
Patent number: 10258681Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.Type: GrantFiled: June 19, 2017Date of Patent: April 16, 2019Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
-
Publication number: 20170290903Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.Type: ApplicationFiled: June 19, 2017Publication date: October 12, 2017Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
-
Patent number: 9730995Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.Type: GrantFiled: September 21, 2015Date of Patent: August 15, 2017Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
-
Patent number: 9528086Abstract: A genetically attenuated Bordetella pertussis strain includes a mutated pertussis toxin (ptx) gene, and a heterologous ampG gene, and a hybrid protein including the N-terminal fragment of filamentous haemagglutinin (FHA) and a heterologous epitope or antigenic protein or protein fragment, different from FHA. The strain can be used in an attenuated vaccine for the treatment or prophylaxis of an infectious disease.Type: GrantFiled: April 9, 2015Date of Patent: December 27, 2016Assignees: UNIVERSITÉ DROIT ET SANTÉ LILLE II, INSERM, INSTITUT PASTEUR DE LILLEInventors: Camille Locht, Nathalie Mielcarek, Hana Kammoun
-
Publication number: 20160045587Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.Type: ApplicationFiled: September 21, 2015Publication date: February 18, 2016Inventors: Camille LOCHT, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
-
Patent number: 9180178Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.Type: GrantFiled: March 16, 2015Date of Patent: November 10, 2015Assignees: Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
-
Patent number: 9119804Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.Type: GrantFiled: March 7, 2007Date of Patent: September 1, 2015Assignees: Institut Pasteur de Lille, Institut National de la Sante et da la Recherche MedicaleInventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
-
Publication number: 20150210978Abstract: A genetically attenuated Bordetella pertussis strain includes a mutated pertussis toxin (ptx) gene, and a heterologous ampG gene, and a hybrid protein including the N-terminal fragment of filamentous haemagglutinin (FHA) and a heterologous epitope or antigenic protein or protein fragment, different from FHA. The strain can be used in an attenuated vaccine for the treatment or prophylaxis of an infectious disease.Type: ApplicationFiled: April 9, 2015Publication date: July 30, 2015Inventors: Camille LOCHT, Nathalie MIELCAREK, Hana KAMMOUN
-
Publication number: 20150202278Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.Type: ApplicationFiled: March 16, 2015Publication date: July 23, 2015Inventors: Camille LOCHT, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
-
Publication number: 20090246222Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.Type: ApplicationFiled: March 7, 2007Publication date: October 1, 2009Applicants: Institute Pasteur de Lille, Institute National de la Sante de la Recherche Medicale (Inserm)Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
-
Patent number: 6660261Abstract: The invention concerns a Bordetella strain deficient in the production of toxin and expressing a hybrid protein comprising at least part of the filamentous hemagglutin (FHA) and at least part of a protein heterologous to FHA. The gene coding for the toxin has been eliminated, or at least partially deleted or mutated so as to produce an inactive toxin. This strain can be used as vaccine. The invention also concerns liposomes containing at least part of the FHA protein and at least one protein heterologous to the FHA protein, and the use of FHA for the stimulation of immune responses.Type: GrantFiled: September 16, 1999Date of Patent: December 9, 2003Assignee: Institut Pasteur de LilleInventors: Nathalie Mielcarek, Camille Locht, Gilles Riveau, Odile Poulain-Godefroy, André Capron